2nd Circ. Affirms Dismissal Of Lipitor Off-Label Marketing Suit
The Second Circuit will not revive a former Pfizer medical director's claims that the company helped defraud the federal government after marketing cholesterol drug Lipitor off-label, saying that prescribing guidelines on...To view the full article, register now.
Already a subscriber? Click here to view full article